iOMEDICO AG

Industry / private company


Location: Freiburg, Germany (DE) DE

ISNI: -

ROR: https://ror.org/03j5af397

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019) Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al. Conference contribution Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry (2019) Staehler M, Goebell P, Müller L, Emde TO, Wetzel N, Kruggel L, Jänicke M, Marschner N Journal article Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL (2018) Boegemann M, Bedke J, Schostak M, Welslau M, Hering-Schubert C, Wolf T, Schleicher J, et al. Conference contribution Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry (2018) Goebell P, Staehler M, Mueller L, Nusch A, Scheffler M, Sauer A, Von Verschuer U, et al. Journal article Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry (2018) Goebell P, Mueller L, Huebner A, Harich HD, Boller E, Koska M, Jaenicke M, Marschner N Journal article Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry (2017) Goebell P, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry (2017) Goebell P, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) (2017) Sehouli J, Tome O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, et al. Journal article Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry (2017) Staehler M, Mueller L, Goebell P, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma - data from the German prospective RCC-Registry (2017) Staehler M, Goebell P, Mueller L, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution
1 2 3